AMN107
information and resources from the National Cancer Institute
AMN107
An orally available aminopyrimidine with antineoplastic activity. Designed to overcome imatinib resistance, AMN107 is a tyrosine kinase inhibitor that binds to and inhibits the Bcr-Abl fusion protein, an abnormal chimeric tyrosine kinase expressed in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells . This agent also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and for c-kit, a receptor tyrosine kinase activated in gastrointestinal stromal tumor (GIST). AMN107 interrupts phosphorylation of these tyrosine kinases and their downstream signaling targets, resulting in decreased cellular proliferation and the induction of apoptosis. This agent is more potent than imatinib against Ph+ CML cells. AMN107
An orally available aminopyrimidine with antineoplastic activity. Designed to overcome imatinib resistance, AMN107 is a tyrosine kinase inhibitor that binds to and inhibits the Bcr-Abl fusion protein, an abnormal chimeric tyrosine kinase expressed in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells . This agent also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and for c-kit, a receptor tyrosine kinase activated in gastrointestinal stromal tumor (GIST). AMN107 interrupts phosphorylation of these tyrosine kinases and their downstream signaling targets, resulting in decreased cellular proliferation and the induction of apoptosis. This agent is more potent than imatinib against Ph+ CML cells.
|
|
|
|
news articles
Novartis May Pay SGX More Than $515 Million in Accord (Update3) Mar 28, 2006
Bloomberg Novartis has been working on its own follow-up medicine AMN107, and has also been studying different doses of Gleevec to combat resistance. ...
SGX Pharmaceuticals Announces Strategic Collaboration to Develop ... Mar 29, 2006
Webbolt Business News, ...their extensive experience developing and commercializing Gleevec as well as development of the novel investigational compound, nilotinib/AMN107, we believe ...
SGX, Novartis Sign $515M Deal Mar 28, 2006
Red Herring, Novartis has also been working on a drug, AMN107, which has helped about half the patients it tested who were afflicted with an aggressive form of CML.
FDA Prioritizes Bristol Drug Mar 7, 2006
Red Herring, Novartis has also been developing a drug known as AMN107 that is also designed to combat the drug resistance problem in Imatinib. ...
AMN107 May Benefit Leukemia Patients Resistant to Gleevec ... Dec 12, 2005
DG News ATLANTA, GA -- December 12, 2005 -- The targeted agent AMN107 may be beneficial for some leukemia patients who are resistant to Gleevec (imatinib mesylate ...
AMN107 Has Potent Activity in Leukemia Resistant to Gleevec Dec 10, 2005
Newswise (press release) Newswise — The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard ...
AMN107 can produce benefits in patients with some forms of ... Dec 12, 2005
Xagena.it, Researchers at The University of Texas MD Anderson Cancer Center found that AMN107 can produce dramatic benefits in patients with some forms of leukemia that ...
Drug Could Augment or Replace Gleevec Dec 5, 2005
CancerWise An oral investigational drug, AMN107, is producing powerful responses for people resistant to Gleevec®, the medication that helps most chronic myeloid ...
Novel Drug Shows Strong Efficacy in Imatinib-Resistant Leukemia Dec 13, 2005
Cancerpage.com, ...lymphocytic leukemia (Ph+ ALL). Investigators are predicting that AMN107 will become the standard of care for these leukemias. At the 47th ...
New studies identify advances in treatment of chronic myeloid ... Dec 13, 2005
Innovations-Report, Both dasatinib and AMN107 have been shown to be effective in treating patients with CML whose disease has progressed on imatinib. ...
Novartis Oncology - Highlights of Key Data Presented at ASH 2005 ... Dec 14, 2005
Business Wire (press release), Management reported that in Glivec it has further established an outstanding track record of efficacy and safety in CML. In AMN107, the Co. ...
Bristol-Myers' Cancer Drug May Benefit Patients, Study Shows Dec 10, 2005
Bloomberg Dasatinib may eventually compete with Novartis' AMN107, which is also being tested in patients with chronic myeloid leukemia resistant to Gleevec. ...
New drug fights leukaemia Dec 12, 2005
Health24.com, The agent, called AMN107 for now, led to marked improvement in all three phases of chronic myeloid leukaemia (CML) and a form of acute lymphocytic leukaemia ...
CML Survival with Gleevec Remains High Dec 12, 2005
MedPage Today, Also at ASH, researchers from the MD Anderson Cancer Center in Houston reported that AMN107, a follow-on compound to Gleevec, appears to be effective against ...
|
|
